Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: Safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 97, Issue 3, 2003, Pages 365-368

  Kamil, A A ^a   Khalil, E A G ^a   Musa, A M ^a   Modabber, F ^b   Mukhtar, M M ^a   Ibrahim, M E ^a   Zijlstra, E E ^a,f   Sacks, D ^c   Smith, P G ^d   Zicker, F ^e   El Hassan, A M ^a  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b Infectious Diseases Research Institute   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f UNIVERSITY OF MALAWI   (Malawi)

Author keywords

Alum; Bacille Calmette Gu rrin; Leishmania major; Sudan; Vaccine; Visceral leishmaniasis

Indexed keywords

BCG VACCINE; LEISHMANIA VACCINE;

ADOLESCENT; ADULT; AGGLUTINATION TEST; ARTICLE; AUTOCLAVE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LEISHMANIA MAJOR; MALE; NORMAL HUMAN; OUTCOMES RESEARCH; SKIN TEST; SKIN ULCER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUDAN; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADULT; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, PROTOZOAN; BCG VACCINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; LEISHMANIA MAJOR; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PROTOZOAN VACCINES; SKIN TESTS; VACCINES, COMBINED;

LEISHMANIA MAJOR; MYCOBACTERIUM BOVIS BCG;

EID: 4444327985     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(03)90171-4     Document Type: Article

References (28)

1. Badaro R. Jones T.C. Carvalho E.M. Sampaio D. Reed S.G. Barral A. Teixeira R. Johnson Jr. W.D. New perspectives on a subclinical form of visceral leighmaniasis Journal of Infectious Diseases 154 1986 1003-1011
2. Bahar K. Dowlati Y. Shidani B. Alimohammadian M.H. Khamesipour A. Ehsasi S. Hashemi-Fesharki R. Ale-Agha S. Modabber F. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers Clinics in Dermatology 14 1996 489-495
3. Castes M. Blackwell J. Trujillo D. Formica S. Cabrera M. Zorrilla G. Rodas A. Castellanos P.L. Convit J. Immune responses in healthy volunteers vaccinated with killed leishmanial promatigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production Vaccine 12 1994 1041-1051
4. Convit J. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela Clinics in Dermatology 14 1996 479-487
5. Dube A. Sharma P. Srivastava J.K. Misra A. Naik S. Katiyar J.C. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG Parasitology 116 1998 219-221
6. El-Hag I.A. Hashim F.A. El-Toum I.A. Homeida M.M.A. El-Kalifa M.Y. El-Hassan A.M. Liver morphology and function in visceral leishmaniasis (kala-azar) Journal of Clinical Pathology 47 1994 547-551
7. El-Hassan A.M. Hashim F.A. Ali M.S. Ghalib H.W. Zijlstra E.E. Kala-azar in western Upper Nile province in the southern Sudan and its spread to a nomadic tribe from the north Transactions of the Royal Society of Tropical Medicine and Hygiene 87 1993 395-398
8. El-Hassan A.M. Zijlstra E.E. Ismael A. Ghalib H.W. Recent observations on the epidemiology of kala-azar in the eastern and central states of the Sudan Tropical and Geographical Medicine 47 1995 151-156
9. Ghalib H.W. Piuvezam M.R. Skeiky Y.A. Siddig M. Hashim F.A. El-Hassan A.M. Russo D.M. Reed S.G. Interleukin 10 production correlates with pathology in human Leishmania donovani infections Journal of Clinical Investigations 92 1993 324-329
10. Greenblatt C.L. Cutaneous leishmaniasis: The prospects for a killed vaccine Parasitology Today 4 1988 53-54
11. Gupta R.K. Siber G.R. Adjuvants for human vaccines: current status, problems and future prospects Vaccine 13 1995 1263-1276
12. Gupta R.K. Relyveld E.H. Lindblad E.B. Bizzini B. Ben-Efraim S. Gupta C.K. Adjuvants: A balance between toxicity and adjuvanticity Vaccine 11 1993 293-306
13. Harith A.E. Kolk A.H. Kager P.A. Leeuwenburg J. Faber F.J. Muigai R. Kiungu S. Laarman J.J. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmanisis: Comparison with IFAT and ELISA Transactions of the Royal Society of Tropical Medicine 81 1987 603-606
14. Hashemi-Fesharki R. Ale-Agha S. Habibi G.R. Manhouri H. Esmail-Nia K. Mohammadi A.A. Ahourai P. Vand-Yousefi G. Bahar K. Dowlati Y. Khamesipour A. Modabber F. Production of inactivated Leishmania major vaccine Iranian Journal of Medical Sciences 23 1998 74-80
15. Jankovic D. Caspar P. Zweig M. Garcia-Moll M. Showalter S.D. Vogel F.R. Sher A. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type-1 cytokine responses to HIV-1 gp120 Journal of Immunology 159 1997 2409-2417
16. Kenney R.T. Sacks D.L. Sypek J.P. Vilela L. Gam A.A. Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis Journal of Immunology 163 1999 4481-4488
17. Khalil E.A. G.El-Hassan A.M. Zijlstra E.E. Mukhtar M.M. Ghalib H.W. Musa B. Ibrahim M.E. Kamil A.A. Elsheikh M. Babiker A. Modabber F. Autoclaved Leishmania major vaccine for the prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in the Sudan Lancet 356 2000a 1565-1569
18. Khalil E.A.G. El-Hassan A.M. Zijlstra E.E. Mukhtar M.M. Ibrahim M.E. Safety and immunogenicity of an autoclaved Leishmania major vaccine East African Medical Journal 77 2000b 468-470
19. Kurtzhals J.A. Hey A.S. Theander T.G. Odera E. Christensen C.B. Githure J.I. Koech D.K. Schaefer K.U. Handman E. Kharazmi A. Cellular and humoral immune responses in a population from the Baringo district of Kenya to Leishmania promastigotes lipophosphoglycan American Journal of Tropical Medicine and Hygiene 46 1992 480-488
20. Mahon B.P. Ryan M.S. Griffin F. Mills K.H. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Thl cells Infection and Immunity 64 1996 5295-5301
21. Misra A. Dube A. Srivastava B. Sharma P. Srivastava J.K. Katiyar J.C. Naik S. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG Vaccine 19 2001 3485-3492
22. Modabber F. Experience with vaccines against cutaneous leishmaniasis of man and mice Parasitology 98 1989 S49-S60
23. Montalban C. Calleja J.L. Erice A. Laguna F. Clotet B. Podzamczer D. Coba J. Mallolas J. Yebra M. Gallego A. Visceral leishmaniasis in patients infected with immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS Journal of Infection 21 1990 261-270
24. Sacks D.L. Lal S.L. Shrivastava S.N. Blackwell J. Neva F.A. An analysis of T-cell responses in Indian kala-azar Journal of Immunology 138 1987 908-913
25. Satti I.N. Osman H.Y. Daifalla N.S. Younis S.A. Khalil E.A.G. Zijlstra E.E. El-Hassan A.M. Ghalib H.W. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers Vaccine 19 2001 2100-2106
26. Smrkovski L.L. Larson C.L. Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani Infection and Immunity 18 1977 561-562
27. Weintraub J. Weinbaum F.I. The effect of BCG on experimental cutaneous leishmaniasis in mice Journal of Immunology 118 1977 2288-2290
28. Zijlstra E.E. El-Hassan A.M. Ismael A. Ghaib H.W. Endemic kala-azar in eastern Sudan: A longitudinal study on the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis American Journal of Tropical Medicine and Hygiene 51 1994 826-836